technetium-tc-99m-medronate and Urogenital-Neoplasms

Bone scintigraphy with 99mtechnetium-labelled polyphosphonates is the most sensitive test for early detection of skeletal metastases. Bone metastases are a major factor in prognosis and have a considerable influence on the therapy selected. In patients with prostate cancer, we recommend routine bone scintigraphy in the initial staging. Follow-up bone scans are indicated whenever a patient develops pain, an elevated level of acid phosphatase, or a rise in prostate specific antigen (PSA). Routine bone scans are not necessary for the initial staging of patients with renal cell carcinomas, bladder carcinomas and testicular tumours. Scans should be routinely performed, however, in patients with bone pain or elevated alkaline phosphatase or when radiological findings are inconclusive. Bone scanning is necessary in patients with neuroblastoma, both for the initial diagnosis and during follow-up in all cases with known skeletal involvement. In addition, bone scintigraphy should be performed in cases of recurrent or suspected malignant phaeochromocytoma as a complement to scintigraphy with iodine-123- or iodine-131-MIBG, respectively. Even though skeletal scintigraphy is a very sensitive test, it lacks specificity. This can be compensated, however, by careful interpretation of the scan in the light of the patient's history and the clinical findings. As a positive side-effect, bone scanning--especially in the form of multiphase scintigraphy--may detect renal abnormalities, concurrent diseases or complications in the upper or lower urinary tract. If scintigraphic findings are doubtful, plain film radiographs are required or, in selected cases, bone biopsy must be performed.

Topics: Adult; Bone Neoplasms; Diagnosis, Differential; Female; Follow-Up Studies; Humans; Male; Radionuclide Imaging; Technetium Tc 99m Medronate; Urogenital Neoplasms

Bone marrow immunoscintigraphy using a 99mTc-labelled anti-NCA-95 monoclonal antibody and conventional bone scintigraphy with 99mTc-methylene-diphosphonate were compared in the diagnosis of skeletal metastases in 58 patients with urogenital tumours. In 13 patients with metastatic disease, bone marrow immunoscintigraphy proved to be superior to bone scintigraphy, detecting 431 metastatic lesions on immunoscans as compared to 261 lesions on bone scans. However, on a patient-by-patient basis bone marrow immunoscintigraphy did not demonstrate a clinical advantage over conventional bone scanning, as in this study no patient was identified with metastatic disease still confined to the marrow space, with bone scintigraphy and bone X-ray being normal.

Topics: Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Bone and Bones; Bone Marrow; Bone Neoplasms; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Cell Adhesion Molecules; Humans; Male; Membrane Glycoproteins; Middle Aged; Prospective Studies; Radioimmunodetection; Technetium Tc 99m Medronate; Urogenital Neoplasms

In order to investigate the feasibility of the assessment of renal function with 99mTc-MDP, we compared renographical images, renogram patterns and the glomerular filtration rate (GFR) obtained by means of a modified Gates' method and 200 MBq of 99mTc-MDP with those obtained by means of 99mTc-DTPA. Because 19 of 20 patients had malignant tumors in the genitourinary tract, there was no difference between the two tracers in identifying a parenchymal defect corresponding to renal cancer. Of eight patients with hydronephrosis, four had a defect or decreased uptake with a dilated pelvis, whereas the other four had marked radioisotope retention in the renal pelvis or the whole kidney on serial images. There was also no difference between the two tracers in identifying hydronephrosis. Of 38 paired renograms 35 showed the same renogram patterns with both tracers. Of three patients with different renogram patterns, two had hydronephrosis. In 20 patients including three patients with bone metastasis, total GFR and split GFR obtained with both tracers correlated with a correlation coefficient of r = 0.920 (p < 0.001) and r = 0.944 (p < 0.001), respectively. Excluding bone metastasis from the analysis, a linear-regression analysis showed excellent agreement between the two measurements with a correlation coefficient of r = 0.960 (p < 0.001) and r = 0.963 (p < 0.001), respectively. The linear regression equations were Y = 1.009X - 0.111 and Y = 1.034X - 0.714, respectively. In conclusion, 99mTc-MDP can be used as a supplement to evaluate renal function incidental to the survey of bone metastases in patients with malignant tumor.

Topics: Aged; Aged, 80 and over; Blood Urea Nitrogen; Bone and Bones; Bone Neoplasms; Creatinine; Female; Glomerular Filtration Rate; Humans; Hydronephrosis; Kidney; Kidney Neoplasms; Male; Middle Aged; Prostatic Neoplasms; Radioisotope Renography; Radiopharmaceuticals; Technetium Tc 99m Medronate; Tissue Distribution; Urinary Bladder Neoplasms; Urogenital Neoplasms

Solitary lesions on bone scans obtained as part of metastatic diagnostic studies for genitourinary malignancy require identification as to whether they represent nonneoplastic or neoplastic disease and, if neoplastic, whether metastatic genitourinary cancer or another primary is present. Such definition requires at least plain film tomograms of the area as well as computerized tomography (for inaccessible lesions) and/or biopsy of lesions still in doubt after tomography. Of the 9 patients in our study 4 had true positive scans for metastatic disease, 3 had false positive scans, 1 had a true positive scan for a second bone primary and 1 is indeterminate, since a negative biopsy of a positive area on a bone scan was followed rapidly by the appearance of other widespread metastases.

Topics: Adenocarcinoma; Adult; Aged; Bone Neoplasms; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Diphosphonates; False Positive Reactions; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Prostatic Neoplasms; Radionuclide Imaging; Technetium; Technetium Tc 99m Medronate; Urinary Bladder Neoplasms; Urogenital Neoplasms